echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > What is the general situation of clinical research on stem cell treatment of freezing disease?

    What is the general situation of clinical research on stem cell treatment of freezing disease?

    • Last Update: 2020-09-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The March 2020 article, published in the Journal of Neurology of the American Medical Association, highlights the limited clinical research opportunities for patients with amyotrophic lateral sclerosis, commonly known as freezing.
    article describes a young woman's husband, a 38-year-old neurologist, suffering from amyotrophic lateral sclerosis, which worsens.
    after the conventional treatment was ineffective, he received stem cell therapy.
    also this year, researchers at Pomelania Medical University in Poland published a study in the International Journal of Medicine called "Family lineage-negative amyotrophic lateral sclerosis patients recover from joint movement after cell therapy - preliminary report."
    in this small stem cell therapy study, 12 adults with amyotrophic lateral sclerosis were able to improve their speech skills after 28 days of stem cell therapy.
    with the development of cell therapy, more and more patients with freezing disease have participated in the clinical study of stem cells and have been alleviated.
    , what is the current clinical profile for stem cell treatment of freezing disease? Clinically, there is an urgent need to develop more effective therapies for freezing, a fatal disease of motor neuron degeneration of the brain and spinal cord, characterized by motor neurodegeneration of the brain and spinal cord, respiratory dysfunction and failure caused by the aggressive paralysis of the shin muscles and other respiratory muscles, which are the most common causes of death in patients with freezing.
    type of disease, exudation or familial, people with lysophobia usually die of respiratory failure within 3-5 years of diagnosis.
    of capillaries in the central nervous system is one of the disease factors in patients with freezing disease, and patients may experience microvascular damage outside the central nervous system, such as microvascular damage in the lungs, which can affect respiratory function.
    the 2014 Frozen Ice Bucket Challenge, launched by former baseball players at Boston College, became a global hit, with bigwigs from all walks of life wetting up and more people aware of the rare disease of freezing.
    was approved in 1994 to treat freezing disease, but it can only extend life expectancy by about three months.
    2017, a new drug, Itala, was registered in the United States.
    currently, Liluazole and Radicava are the ® FDA-approved treatments.
    these drugs have some survival benefits, they cannot be reversed or cured.
    the inability of the percepitative breathing muscle leads to impaired function of the shin muscle, and patients often have ineffective breathing and pneumonia.
    a recent study, respiratory dysfunction in patients with freezing is associated with weakness of the spinal cord muscles in the neck.
    these complications require palliative methods, such as tracheotomy or respiratory intives, to support ventilation, which can prolong the patient's survival and improve the quality of life for at least two years.
    but because about 95 percent of people with freezing disease in the United States refuse to be implanted with mechanical ventilators, the treatment of respiratory failure is a clinical need that needs to be met in addition to developing effective treatment strategies.
    stem cells are expected to be a promising treatment for freezing disease as a new option for the treatment of freezing disease.
    the main objectives of this treatment strategy are cell replacement and nerve protection.
    study found that multiple stem cells and progeny cells have the potential to directly replace motor neurons and lesions of glial cells, or as a strategy to slow disease degradation.
    although intercomponent stem cells are well known to differentiate into nerve cells and glials, stem cell/substring cell therapy has only been proposed in the past few years to treat freezing disease.
    , for example, phase I/IIa clinical trials of interstitating stem cells injected into patients have shown that this therapy provides potential neurotrophic support for motor neurons and demonstrates the safety and effectiveness of treatment.
    also found that the treatment of in vitro neural stem cells combined with T-cell injection may be a viable way to treat lysophobia.
    addition, self-hematopoietic stem cell transplantation of the motor cortical cortical layer of the forehead of patients with freezing disease has also been shown to be safe, and the patient's tolerance has been excellent.
    2019, the FDA and a team of experts issued guidelines for clinical studies of lysophobic disease, with the aim of exploring its clinical and genetic biomarkers.
    in addition to reporting general efficacy, an important issue is the prediction of the response to interstuming stem cell therapy.
    experts point out that interstitiotic stem cell therapy can significantly reduce the rate of development of the disease and triple the survival rate.
    treatment is even better than the registered drug Ida Lafeng.
    and effectiveness of interstate-charged stem cell therapy have been confirmed.
    currently, several clinical trials have been approved for the use of interstumogenic stem cells to treat freezing disease.
    , stem cell therapy for freezing is growing so rapidly that new stem cell drugs are now in the late stages of clinical trials.
    , for example, NurOwn®, a stem cell drug for freezing, is in Clinical Phase III, or will be the world's first freezing stem cell therapy drug.
    2014, the treatment has been designated by the FDA's Fast Track product.
    Looking ahead, further research is expected to provide a clearer understanding of the potential of stem cell immunomodulation, tissue repair, release of nutrient factors, secretion of exosomes and homecoming effects, making stem cell therapy a safe and effective new way of freezing intervention.
    of course, stem cell therapy still has a lot of problems to solve for freezing.
    from the current clinical data, there is a certain delay in the treatment effect of the disease, but more clinical trials and scientific research to explore the process of optimization to achieve the best results.
    References: 1. Vijayaraghavan, M. (2020). Improving access to clinical trials for amyotrophic lateral sclerosis treatment. JAMA Neurology, 77, 671.2. Wioletta Pawlukowska1, Bart?ogij Baumert 2, Monika Gołąb-Janowska 3, et.al Articulation Recovery in ALS patients after lineage-negative adjuvant cell therapy - preliminary report. Int J Med Sci 2020; 17(13):1927-1935. doi: 10.7150/ijms.470023. Svitlana Garbuzova-Davis, Robert Shell, Hilmi Mustafa, et.al Advancing Stem Cell Therapy for Repair of Damaged Lung Microvasculature in Amyotrophic Lateral Sclerosis. Cell Application. Jan-Dec 2020;29:963689720913494. doi: 10.1177/09636897209134944. Björn Oskarsson, Tania F Gendron, Nathan P Staff Amyophic Lateral Sclerosis: An Update for 2018.Mayo Clin Proc.2018 Nov; 93 (11): 1617-1628.doi: 10.1016/j.mayocp.2018.04.007.5. Jun Ma, Baofeng Feng, Desheng Kong, et.al Production and validation of human induced pluripotent stem cell line from sporadic amyophic lateral sclerosis (SALS). Stem Cell Res.2020 Apr;44:101760. doi: 10.1016/j.scr.2020.101760. Epub 2020 Mar 13.6. Johannes P J M de Munter, Igor Shafarevich, Alexei Liundup, et.al Neuro-Cells therapy improves motor outcomes and suppresses when the experiment syndrome of amyophic lateral sclerosis in mice. CNS Neurosci Ther.2020 May;26 (5):504-517.doi: 10.1111/cns.13280. Epub 2019 Dec 23.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.